A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950)

Authors:

Abstract
Background: INI1 loss may occur in tumors exhibiting rhabdoid morphology, including sinonasal carcinoma (SNC) and spindle cell sarcoma (SCS). Loss of INI1, a critical subunit of the SWI/SNF complex, leads to oncogenic dependence on EZH2 through transcriptional repression caused by aberrant H3K27me3. Tazemetostat, a potent, selective, oral inhibitor of EZH2, has demonstrated tumor regression in INI1-negative preclinical models and clinical activity in phase 1 trials with INI1-negative tumors.